Skip to Content Facebook Feature Image

Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets

Business

Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets
Business

Business

Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets

2025-03-17 21:00 Last Updated At:21:15

SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- Galux Inc., a South Korean startup specializing in AI-driven protein therapeutics design, has published a study showcasing the capabilities of its AI platform, GaluxDesign, in de novo antibody design. This research marks an important milestone in AI-driven antibody discovery, demonstrating the successful design of antibodies against six distinct therapeutic targets, including a target without an experimentally resolved structure.

"De novo antibody design has been one of the major challenges in AI-based drug discovery, requiring atomic-level precision to ensure specific binding to target epitopes," said Chaok Seok, CEO of Galux. "A few previously reported cases of de novo antibody design have shown only limited success, particularly in terms of target diversity and binding affinity. Our findings prove that AI can reliably generate novel antibodies with high precision, specificity, and sensitivity across diverse therapeutic targets."

A graphical representation verifying the binding strength between the antibodies designed by GaluxDesign and each therapeutic target.

The study presents an AI-driven approach to de novo antibody design. The team identified binders from a yeast display single-chain variable fragment (scFv) library comprising approximately one million designed antibody sequences, followed by screening binders against a target protein. Binders with varying binding strengths were identified for six targets, including PD-L1, HER2, EGFR(S468R), ACVR2A/B, FZD7, and ALK7.

Notably, the team successfully designed antibodies targeting ALK7, a protein without an experimentally resolved structure, as well as antibodies targeting a novel epitope of FZD7 discriminating subtypes FZD1 and FZD5. This highlights the platform's broad applicability for novel antibody discovery.

The designed PD-L1 targeting antibody showed outstanding binding affinity (KD=9.0pM) and developability comparable to the commercial therapeutic antibody Atezolizumab. Additionally, antibodies designed for EGFR(S468R) displayed exceptional specificity, precisely distinguishing the mutant from wild-type EGFR based on a single amino acid difference, which is an essential feature for minimizing off-target effects in early-stage drug development.

"This study underscores the potential of AI-driven antibody design and its broad applicability in antibody discovery," added Seok. "By continuously advancing our AI platform with a deep understanding of atomic-level protein interactions, we aim to transform therapeutic drug discovery, improving both efficiency and success rates."

The full research paper is available here: https://www.biorxiv.org/content/10.1101/2025.03.09.642274v1

About Galux

With over 25 years of expertise in the field, Galux is pioneering AI-powered protein design with its proprietary platform, GaluxDesign, which enables precise de novo protein design and engineering. GaluxDesign has been developed to deeply understand the physical principles that govern protein folding and interactions. This approach enables the platform to tackle various protein design challenges including epitope-specific antibody design. Since its incorporation in 2020, the company has raised USD 18 million from reputable investors, including InterVest, Pathway Partners, DAYLI Partners, LG Corp., and KDB Capital.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets

Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets

DUBAI, UAE, March 19, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has partnered exclusively with the University of Wollongong in Dubai (UOWD) to host a Demo Trading Challenge & Workshop at UOWD campus. This initiative equipped students from Business Analysis, Finance, Accounting, and other business-related disciplines with practical trading knowledge, enhanced their understanding of cryptocurrency markets, and bridged the gap between academic theory and real-world trading strategies.

UOWD, the UAE's first international Australian university, is recognized for its commitment to academic excellence and industry collaboration. Accredited by both the UAE Ministry of Education and Australia's Tertiary Education Quality and Standards Agency (TEQSA), UOWD has played a key role in developing future business and finance leaders.

Bybit leveraged this collaboration to strengthen its ties with UOWD, increase brand visibility within the academic community, and introduce students to the Bybit trading ecosystem. Additionally, this initiative aligned with Bybit's broader strategy to identify and recruit top-tier fresh graduates, expanding its talent pipeline in the region.

The workshop provided participants with hands-on experience using Bybit's demo trading platform, allowing them to navigate market fluctuations in real time while learning key strategies from industry experts. The event culminated in a competitive trading challenge, where students applied their newly acquired knowledge in a dynamic, risk-free environment.

Attendees also gained insights from a lineup of distinguished speakers alongside Bybit's senior product managers specializing in trading bots, copy trading, and demo trading. Their expertise gave students a deeper understanding of spot and contract trading processes, market data analysis, and risk management.

"At Bybit, we believe that financial literacy and hands-on experience are key to unlocking opportunities in the digital economy," said Phoebe Peng, Head of Organization Development at Bybit. "Through this collaboration with UOWD, we empowered the next generation of professionals with the skills and knowledge needed to thrive in the evolving world of cryptocurrency trading."

This partnership underscored Bybit's dedication to fostering financial literacy and talent development within the digital asset ecosystem. Bybit continues to expand its engagement with educational institutions worldwide, creating opportunities for emerging professionals to explore the potential of Web3 and decentralized finance.

#Bybit / #TheCryptoArk

About Bybit

Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 60 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Bybit Partnered with University of Wollongong in Dubai to Host Exclusive Demo Trading Challenge

Bybit Partnered with University of Wollongong in Dubai to Host Exclusive Demo Trading Challenge

Recommended Articles
Hot · Posts